Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Land & Improvements (2016 - 2019)

Myriad Genetics (MYGN) has disclosed Land & Improvements for 5 consecutive years, with $2.2 million as the latest value for Q3 2019.

  • On a quarterly basis, Land & Improvements fell 8.33% to $2.2 million in Q3 2019 year-over-year; TTM through Sep 2019 was $2.2 million, a 8.33% decrease, with the full-year FY2019 number at $2.3 million, down 4.17% from a year prior.
  • Land & Improvements was $2.2 million for Q3 2019 at Myriad Genetics, down from $2.3 million in the prior quarter.
  • In the past five years, Land & Improvements ranged from a high of $2.5 million in Q4 2017 to a low of $2.2 million in Q4 2016.
  • A 5-year average of $2.3 million and a median of $2.3 million in 2015 define the central range for Land & Improvements.
  • Peak YoY movement for Land & Improvements: grew 13.64% in 2017, then dropped 8.33% in 2019.
  • Myriad Genetics' Land & Improvements stood at $2.3 million in 2015, then fell by 4.35% to $2.2 million in 2016, then increased by 13.64% to $2.5 million in 2017, then fell by 4.0% to $2.4 million in 2018, then fell by 8.33% to $2.2 million in 2019.
  • Per Business Quant, the three most recent readings for MYGN's Land & Improvements are $2.2 million (Q3 2019), $2.3 million (Q2 2019), and $2.3 million (Q1 2019).